Honduras vs Myanmar: Statin use vs. average non-HDL cholesterol levels
Honduras
3.7
in 2018
Myanmar
3.7
in 2018
Honduras rank
12th
Myanmar rank
12th
Statin use vs. average non-HDL cholesterol levels over time
- Honduras
- Myanmar
How they compare
Honduras currently reports 3.7 against 3.7 in Myanmar, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Honduras ahead.
Honduras ranks 12th and Myanmar ranks 12th of 191 countries.
Honduras has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Honduras | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.51 | 3.05 | 0.46 | Honduras |
| 1990s | 3.75 | 3.16 | 0.59 | Honduras |
| 2000s | 3.89 | 3.37 | 0.52 | Honduras |
| 2010s | 3.79 | 3.62 | 0.1667 | Honduras |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Honduras or Myanmar?
- Honduras, at 3.7 against 3.7 in Myanmar as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Honduras and Myanmar?
- 0, with Honduras ahead.
- How many years of comparable data are there for Honduras and Myanmar?
- 39 years are reported by both, from 1980 to 2018.
- How do Honduras and Myanmar rank globally for statin use vs. average non-hdl cholesterol levels?
- Honduras ranks 12th and Myanmar ranks 12th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.